Clinical Trials Using Anti-CD123 ADC IMGN632
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD123 ADC IMGN632. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
IMGN632 as Monotherapy or With Venetoclax and / or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia
This is an open-label, multicenter, Phase 1b / 2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and / or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment.
Location: 12 locations
Study of IMGN632 in Patients With Relapse / Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
This is an open-label, multi-center, Phase 1 / 2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed / refractory BPDCN patients.
Location: 7 locations